Dec 27, 2024 06:01AM
Dec 27, 2024 06:00AM
Dec 9, 2024 08:30PM
Nov 19, 2024 07:00AM
Nov 12, 2024 06:00AM
Oct 16, 2024 06:00AM
Sep 26, 2024 06:21PM BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
Aug 26, 2024 06:00AM
Aug 7, 2024 06:00AM
Jun 14, 2024 06:00AM
May 8, 2024 06:00AM
Apr 23, 2024 06:00AM
Apr 23, 2024 06:00AM
Mar 14, 2024 04:30PM BeiGene (BGNE) Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic ESCC After Prior Chemotherapy
Mar 14, 2024 04:28PM
Mar 14, 2024 10:12AM
Mar 8, 2024 06:08AM
Mar 7, 2024 05:19PM
Mar 7, 2024 05:19PM
Feb 29, 2024 10:02AM
Feb 27, 2024 06:02AM BeiGene's (BGNE) BLA for TEVIMBRA Accepted by FDA
Feb 27, 2024 06:00AM
Feb 26, 2024 06:00AM
Feb 26, 2024 05:49AM
Feb 26, 2024 05:00AM
Dec 22, 2023 06:00AM
Dec 22, 2023 06:00AM
Nov 9, 2023 04:01PM BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates
Oct 17, 2023 04:02PM
Oct 17, 2023 04:01PM
Oct 17, 2023 04:01PM
Oct 16, 2023 06:00AM
Sep 19, 2023 06:15AM
Sep 19, 2023 06:15AM
Aug 2, 2023 06:00AM BeiGene Accelerates Global Momentum with Strong Second Quarter 2023 Financial Results
Jul 12, 2023 07:03AM
Jul 12, 2023 07:00AM
May 4, 2023 07:00AM
Apr 20, 2023 07:03AM
Apr 20, 2023 07:00AM
Apr 17, 2023 02:32PM
Apr 17, 2023 02:32PM SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Assoc
Apr 17, 2023 02:30PM
Apr 17, 2023 02:30PM
Mar 21, 2023 07:01AM
Mar 21, 2023 07:00AM
Mar 16, 2023 04:15PM
Feb 27, 2023 07:00AM
Feb 24, 2023 07:02AM BeiGene (BGNE) Receives 10th Approval for PD-1 Inhibitor Tislelizumab in China
Feb 24, 2023 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All